期刊文献+

冠状动脉三支病变34例危险因素分析 被引量:2

Analysis of the risk factors for three-vessel coronary disease:A report of 34 cases
下载PDF
导出
摘要 目的 :探讨冠状动脉三支病变与危险因素之间的关系。方法 :对 34例冠心病三支病变患者与 6种心血管危险因素 (高血压、高脂血症、高龄、吸烟、性别、高血糖 )进行回顾性分析。结果 :30例 (占 88.2 % )患者具备 3种及 3种以上危险因素 ,≤ 2种危险因素患者仅占 11.8%。结论 :冠心病三支病变具有多种危险因素聚集倾向。 Objective:To explore the relationship between the risk factors and three vessel coronary artery lesions.Methods:The clinical data of 34 patients with angiographically defined three vessel coronary artery disease and the related risk factors(hypertension,age,gender,tobacco use,hyperlipidemia,hyperglycemia) were analysed retrospectively.Results:Of 30(88.2%) patients were presented with 3 or more than 3 risk factors;4(11.8%) patients exhibited 1 or 2 risk factors.Conclusions:Three vessel coronary artery disease possesses the aggregative tendence of risk factors.
出处 《蚌埠医学院学报》 CAS 2003年第5期406-407,共2页 Journal of Bengbu Medical College
关键词 冠状动脉疾病 危险因素 coronary disease risk factors
  • 相关文献

参考文献5

  • 1徐成斌.冠心病防治在调脂领域的某些进展与动向[J].心血管病学进展,2002,23(1):1-5. 被引量:33
  • 2田声放,李长贵,康维强,乔树宾,松尾修三.冠心病患者冠状动脉病变与糖耐量变化的关系[J].中华内分泌代谢杂志,2002,18(4):289-292. 被引量:38
  • 3叶任高 陆再英.动脉粥样硬化和冠状动脉粥样硬化性心脏病[A]..内科学 第5版[C].北京:人民卫生出版社,2000.27.
  • 4Assmann G, Schulte H. Role of triglycerides in coronary artery disease:Lessons from the Prospective Cardiovascular Munster Study[J]. Am J Cardiol, 1992,70(19) : 10H-13H.
  • 5Sigurdsson GJr, Gudnason V, Sigurdsson G, et al. Interaction between a polymorphism of the ApoA-I promoter region and smoking determines plasma levels of HDL and ApoA-I [ J ].Arterioscler Thromb, 1992,12(9) : 1 017- 1 OP?.

二级参考文献24

  • 1[1]Scandinavian Simvastatin Survival Study Group. Randomise d trial of choles terol lowering in 4 444 patients with coronary heart disease: the Scandinavian Survival Study(4S)[J]. Lancet,1994,344:1383-1389.
  • 2[2]Sacks FM,Pfeffer MA,Moye LA,et al. The effect of pravastatin on coro nary events after myocardial infarction in patients with average cholesterol evels. Cholesterol and Recurrent Events Trial Ingestigarors[ J ]. N Engl J Med, 1996,335: 1001-1009.
  • 3[3]The Long-Term Intervention with Pravastatin in Ischemie Heart Disease (LIPID)Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of ini tial cholesterol Levels[J]. N Engl J Med,1998,339:1349-1357.
  • 4[4]Shepherd J,Cobbe SM,Ford 1,et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scot[and coronary prevention Study Group[J ]. N Engl J Med, 1995,333: 130l-1307.
  • 5[5]Downs JR,Clearfield M,Weis S,et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels Re sults of AFCAPS/Tex CAPS[J]. JAMA,1998,279:1615-1622.
  • 6[6]The lipid research clinics coronary primary prevention trial results. I reduc tion in incidence of coronary heart disease[J]. JAMA. 1984,251: 351-364
  • 7[7]NCEP(National Cholesterol Education Program). Guidelines of the second adult treatment panel( ATP I )[J]. JAMA,1993,267:3015-3023.
  • 8[8]The Post Coronary Artery Bypass Graft Trial Invesugators. The effect of aggressive lowering of low-density lipoprotein cholesterol levels and low dose anticoagulation on obstructive changes in saphenous-vein coronary artery bypass grafts[J ]. N Engl J Med,1997,336:153-162.
  • 9[9]Pitt B,Waters D,Brown WV,et al. Aggressive lipid lowering therapy compared with angioplasty in stable coronary artery disease[J]. N Engl J Med,1999,341:70-76.
  • 10[10]Davignon J. Pleiotropic effects: facts and fiction XⅢ International Symposium on Atherosclerosls[R]. Sweden Stockholm: 2000-1 25~29.

共引文献70

同被引文献17

引证文献2

二级引证文献24

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部